Aquestive Therapeutics AQST 深 沪
交易中 06-25 11:44:33 美东时间
4.285
-0.705
-14.13%
华盛通- 最 高4.90
- 今 开4.90
- 成交量 197.83万股
- 最 低 4.2501
- 昨 收 4.99
- 总市值 5.38亿
- 52周最高 7.55
- 市盈率 静 --
- 换手率 1.58%
- 52周最低 2.93
- 委 比 29.00%
- 总股本 1.25亿
- 历史最高 20.696
- 量 比 2.64
- 振 幅 13.02%
- 历史最低 0.618
- 每 手 1
- 风险率 1.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aquestive Therapeutics Charts Cautious, Liquid Path Forward
Aquestive Therapeutics, Inc. (($AQST)) has held its Q1 earnings call. Read on f...
05-20 14:56
Aquestive Therapeutics Signals Momentum In Earnings Call
Aquestive Therapeutics, Inc. (($AQST)) has held its Q1 earnings call. Read on f...
05-15 08:26
Aquestive Therapeutics Q1 2026 Earnings Call: Complete Transcript
Aquestive Therapeutics (NASDAQ:AQST) held its first-quarter earnings conference...
05-14 21:09
Aquestive Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.
Aquestive Therapeutics shares are trading higher after the company reported bet...
05-14 04:40
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $48.072M Est
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $48.072 million estimate.
05-14 04:02
Aquestive Therapeutics Q1 EPS $(0.07) Beats $(0.15) Estimate, Sales $14.446M Beat $10.896M Estimate
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 70.83 percent increase over losses of $(0.24) per share
05-14 04:02
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
Aquestive Therapeutics will report Q1 2026 results and business updates after market close on May 13, 2026. A conference call for investors will be held on May 14 at 8:00 a.m. ET. Registration is required to obtain dial-in details. A live webcast and replay will be available on the Investors section of Aquestive's website. The company specializes in innovative pharmaceuticals, including Anaphylm™ and AQST-108, and operates as a CDMO.
05-06 11:00
Aquestive Therapeutics CLO Thomas Zalewski files initial beneficial ownership statement
Aquestive Therapeutics CLO Thomas Zalewski files initial beneficial ownership statement Aquestive Therapeutics Chief Legal Officer Thomas A. Zalewski filed an initial Form 3 on April 10, 2026, reporting holdings as of April 2, 2026. Disclaimer: This news brief was created by Public Technologies (PUB
04-10 21:56
Aquestive Therapeutics Completes In-Person Type A Meeting With FDA Regarding Resubmission Of NDA For Anaphylm Sublingual Film For Treatment Of Type 1 Allergic Reactions, Including Anaphylaxis
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery
03-30 19:15
